These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31061165)

  • 21. Efficacy of Human-Simulated Epithelial Lining Fluid Exposure of Meropenem-Nacubactam Combination against Class A Serine β-Lactamase-Producing
    Asempa TE; Motos A; Abdelraouf K; Bissantz C; Zampaloni C; Nicolau DP
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections.
    Stewart AG; Harris PNA; Henderson A; Schembri MA; Paterson DL
    J Antimicrob Chemother; 2020 Sep; 75(9):2384-2393. PubMed ID: 32443141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of piperacillin in combination with novel β-lactamase inhibitor IID572 against β-lactamase-producing strains of Enterobacteriaceae and Staphylococcus aureus in murine neutropenic thigh infection models.
    Growcott EJ; Gamboa L; Roth T; Lopez S; Osborne CS
    J Antimicrob Chemother; 2020 Jun; 75(6):1530-1536. PubMed ID: 32108878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-carbapenem β-lactam/β-lactamase inhibitors versus carbapenems for urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: a systematic review.
    Zhang H; Liang B; Wang J; Cai Y
    Int J Antimicrob Agents; 2021 Oct; 58(4):106410. PubMed ID: 34339776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem.
    Griffith DC; Sabet M; Tarazi Z; Lomovskaya O; Dudley MN
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis?
    Stupica D; Lusa L; Klevišar MN; Terzić S; Pirš M; Premru MM; Strle F
    Int J Antimicrob Agents; 2017 Oct; 50(4):564-571. PubMed ID: 28711676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emergency Department Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Many Patients Have No Identifiable Risk Factor and Discordant Empiric Therapy Is Common.
    Frazee BW; Trivedi T; Montgomery M; Petrovic DF; Yamaji R; Riley L
    Ann Emerg Med; 2018 Oct; 72(4):449-456. PubMed ID: 29980462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: current evidence and future prospects.
    Sheu CC; Lin SY; Chang YT; Lee CY; Chen YH; Hsueh PR
    Expert Rev Anti Infect Ther; 2018 Mar; 16(3):205-218. PubMed ID: 29402125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing
    Das S; Johnson A; McEntee L; Farrington N; Kirby A; Unsworth J; Jimenez-Valverde A; Kolamunnage-Dona R; Bousquet J; Alibaud L; Sable C; Zalacain M; Everett M; Hope W
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32778549
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacokinetics-Pharmacodynamics of a Novel β-Lactamase Inhibitor, CB-618, in Combination with Meropenem in an In Vitro Infection Model.
    VanScoy BD; Trang M; McCauley J; Conde H; Bhavnani SM; Friedrich LV; Alexander DC; Ambrose PG
    Antimicrob Agents Chemother; 2016 Jul; 60(7):3891-6. PubMed ID: 27001820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Lampri N; Galani I; Poulakou G; Katsarolis I; Petrikkos G; Giamarellou H; Souli M
    J Antimicrob Chemother; 2012 Oct; 67(10):2424-8. PubMed ID: 22665388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection.
    Berkhout J; Melchers MJ; van Mil AC; Seyedmousavi S; Lagarde CM; Schuck VJ; Nichols WW; Mouton JW
    Antimicrob Agents Chemother; 2016 Jan; 60(1):368-75. PubMed ID: 26525790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extended-spectrum β-lactamase-producing Enterobacteriaceae: in vitro susceptibility to fosfomycin, nitrofurantoin and tigecycline.
    Al-Zarouni M; Senok A; Al-Zarooni N; Al-Nassay F; Panigrahi D
    Med Princ Pract; 2012; 21(6):543-7. PubMed ID: 22722224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
    Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
    Nguyen HM; Shier KL; Graber CJ
    J Antimicrob Chemother; 2014 Apr; 69(4):871-80. PubMed ID: 24265230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
    Mohanty S; Gaind R; Ranjan R; Deb M
    J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo efficacy of human simulated regimens of carbapenems and comparator agents against NDM-1-producing Enterobacteriaceae.
    Wiskirchen DE; Nordmann P; Crandon JL; Nicolau DP
    Antimicrob Agents Chemother; 2014; 58(3):1671-7. PubMed ID: 24379195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an
    VanScoy BD; Tenero D; Turner S; Livermore DM; McCauley J; Conde H; Bhavnani SM; Rubino CM; Ambrose PG
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947475
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Lepak AJ; Zhao M; VanScoy B; Taylor DS; Ellis-Grosse E; Ambrose PG; Andes DR
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.
    Melchers MJ; van Mil AC; Mouton JW
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4521-5. PubMed ID: 25987635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.